NOTE - Mauna Kea Technologies - Acheter, Initiation de couverture - Obj. 0,90€
Nous initions la couverture de Mauna Kea Technologies. Le pivot stratégique qui s'opère actuellement offre de nouvelles perspectives. La transition d'un modèle de ventes en direct de Cellvizio vers un modèle de partenariats devrait permettre à la société de capitaliser à moindres coûts sur la propriété intellectuelle de son innovation de rupture. La JV avec Tasly en Chine est la première pierre à l'édifice.Mauna Kea Technologies is a global medical device company based in France. Co. is focused on innovations in the field of endomicroscopy (microscopic imaging during endoscopy procedures). Co. is predominately active in the advent of optical biopsy. Co. researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Co.'s flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Co. has marketing authorizations in Thailand, United Kingdom, U.S., Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia.
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.